Department of General Surgery, First Affiliated Hospital of Soochow University, Soochow, Jiangsu 215006, China.
Department of General Surgery, Dongtai People's Hospital, Yancheng, Jiangsu 224200, China.
Genet Res (Camb). 2022 Jul 19;2022:7236823. doi: 10.1155/2022/7236823. eCollection 2022.
Liver hepatocellular carcinoma (LIHC) is the predominant type of liver cancer, and its treatment still faces great challenges presently. Mitochondrial inner membrane protein MPV17 is reported to be involved in multiple biological activities of cancers. Here, we seek to investigate the specific role and functions of MPV17 in LIHC progression.
Firstly, MPV17 expressions in various tumors and corresponding normal samples and LIHC groups with various clinical features were analyzed, respectively. Next, the relationship between MPV17 expression and LIHC survival was analyzed and verified by AUC curves. Besides, differentially expressed genes (DEGs) for LIHC were screened from TCGA and then analyzed by GO and KEGG. Then, MPV17 was analyzed by prognostic model, Cox analysis, predictive nomogram, pathway correlation, and immunoassay. Finally, the functions of MPV17 were determined by CCK-8 and Tranwell assays.
In most tumors, MPV17 expression was higher than that in the normal group, and it was related to LIHC clinical features. In the LIHC survival analysis, highly expressed MPV17 was associated with a poor prognosis. Besides, 314 upregulated and 193 downregulated DEGs are mainly involved in the TNF signaling pathway and tyrosine metabolism. Through prognostic model, Cox analysis, and predictive nomogram, MPV17 had the prognostic value for LIHC. Gene-pathway correlation analysis showed that MPV17 had the strongest correlation with the G2M_checkpoint pathway. In an immunoassay, MPV17 had a strong correlation with many immune cells. Functional assays showed that MPV17 reduction in LIHC cells could inhibit cell invasion, migration, and proliferation.
MPV17, as a tumor promoter, could be a new biomarker for LIHC diagnosis and prognosis and probably shed new light on the exploration of LIHC therapies.
肝细胞肝癌（LIHC）是肝癌的主要类型，目前其治疗仍面临巨大挑战。线粒体内膜蛋白 MPV17 据报道参与了癌症的多种生物学活动。在这里，我们试图研究 MPV17 在 LIHC 进展中的具体作用和功能。
首先，分析了各种肿瘤及其相应的正常样本和具有不同临床特征的 LIHC 组中 MPV17 的表达。接下来，通过 AUC 曲线分析和验证了 MPV17 表达与 LIHC 生存的关系。此外，从 TCGA 筛选出 LIHC 的差异表达基因（DEGs），并通过 GO 和 KEGG 进行分析。然后，通过预后模型、Cox 分析、预测列线图、途径相关性和免疫测定分析 MPV17。最后，通过 CCK-8 和 Transwell 测定确定 MPV17 的功能。
在大多数肿瘤中，MPV17 的表达高于正常组，并且与 LIHC 的临床特征有关。在 LIHC 生存分析中，高表达的 MPV17 与预后不良相关。此外，上调的 314 个和下调的 193 个 DEGs 主要参与 TNF 信号通路和酪氨酸代谢。通过预后模型、Cox 分析和预测列线图，MPV17 对 LIHC 具有预后价值。基因途径相关性分析表明，MPV17 与 G2M_checkpoint 途径相关性最强。在免疫测定中，MPV17 与许多免疫细胞有很强的相关性。功能测定表明，降低 LIHC 细胞中的 MPV17 可抑制细胞侵袭、迁移和增殖。
MPV17 作为一种肿瘤促进剂，可能成为 LIHC 诊断和预后的新生物标志物，并可能为探索 LIHC 治疗方法提供新的思路。
